Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s DataResults showed lasofoxifene protected against hormone withdrawal-induced bone loss and maintained a robust anti-tumor response in primary and metastatic animal models of ER+ breast cancer
LeonaBio Reports Full Year 2025 Financial Results and Provides Business UpdateAcquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business OfficerBrings more than 25 years of biopharma business development and corporate strategy expertise
